EU, AstraZeneca Reach Deal to End Vaccine Row

The EU and AstraZeneca, a UK-based Swedish pharmaceutical company, have settled a dispute over a shortage of coronavirus vaccines that hampered the European deployment earlier this year.

The company has agreed to supply 200 million doses of its vaccine to the EU by the end of March 2022, as promised under a deal.

The agreement puts an end to the EU's pending legal action in Belgium.

The EU said this week that 70% of adults had been double vaccinated.

AstraZeneca enraged European Commission officials earlier this year when it stated it would only be able to supply a fraction of the doses agreed upon for the first three months of 2021.